Liensinine affects the dephosphorylation and mitochondrial metastasis of DNM1L, which inhibits the recruitment of RAB7A to lysosomes, thereby blocking autophagosome–lysosome fusion and enhancing doxorubicin-mediated apoptosis, ultimately reducing the activity of breast cancer cells [31]. The gene discussed is DNM1L; the disease is breast cancer.